TIMP1 and AL amyloidosis: Significantly increased serum TIMP-1 levels and a potential poor prognostic role have been reported in patients with melanoma [35], and patients with a variety of cancer types including breast [36,37], prostate [38], gastric [39], colorectal carcinoma [40], glioblastoma [41], and multiple myeloma [42,43].